Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11)

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 47, 2013, Pages 19143-19148

  Chen, Shujuan ^a   Yueh, Mei Fei ^a   Bigo, Cyril ^b   Barbier, Olivier ^b   Wang, Kepeng ^c   Karin, Michael ^c   Nguyen, Nghia ^a   Tukey, Robert H ^a  

^a Departments of Chemistry and Biochemistry and Pharmacology   (United States)

^b Université Laval   (Canada)

^c San Diego   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIRTECAN; GLUCURONOSYLTRANSFERASE 1; GLUCURONOSYLTRANSFERASE 1A1; GLYCOSYLTRANSFERASE; IRINOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CELL LOSS; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG DETOXIFICATION; DRUG DOSE INTENSIFICATION; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG MECHANISM; GENE CONTROL; GENE EXPRESSION; GENE INDUCTION; INFLAMMATION; INTESTINE; INTESTINE TUMOR; LETHALITY; LIVER; LOW DRUG DOSE; MALE; METASTATIC COLORECTAL CANCER; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; WEIGHT REDUCTION;

ANIMALS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE; HISTOLOGICAL TECHNIQUES; IMMUNOBLOTTING; INTESTINES; LIVER; MALE; MICE; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84888092572     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1319123110     Document Type: Article

References (48)

1. Rim SH, Seeff L, Ahmed F, King JB, Coughlin SS (2009) Colorectal cancer incidence in the United States, 1999-2004: An updated analysis of data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results Program. Cancer 115(9-1967-1976.
2. Weir HK, et al. (2003) Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95(17-1276-1299.
3. Pizzolato JF, Saltz LB (2003) The camptothecins. Lancet 361(9376-2235-2242.
4. Pommier Y (2006) Topoisomerase I inhibitors: Camptothecins and beyond. Nat Rev Cancer 6(10-789-802.
5. Smith NF, Figg WD, Sparreboom A (2006) Pharmacogenetics of irinotecan metabolism and transport: An update. Toxicol In Vitro 20(2-163-175.
6. Rothenberg ML, et al. (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11(11-2194-2204.
7. Rowinsky EK, et al. (1994) Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54(2-427-436.
8. Ma MK, McLeod HL (2003) Lessons learned from the irinotecan metabolic pathway. Curr Med Chem 10(1-41-49.
9. Mathijssen RH, et al. (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7(8-2182-2194.
10. Hatfield MJ, et al. (2011) Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. Biochem Pharmacol 81(1-24-31.
11. Sanghani SP, et al. (2003) Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Clin Cancer Res 9(13-4983-4991.
12. Kim TW, Innocenti F (2007) Insights, challenges, and future directions in irinogenetics. Ther Drug Monit 29(3-265-270.
13. Liu CY, et al. (2008) UGT1A1 28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 112(9-1932-1940.
14. Fujiwara R, Nguyen N, Chen S, Tukey RH (2010) Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (UGT1) locus. Proc Natl Acad Sci USA 107(11-5024-5029.
15. Cai H, et al. (2010) A humanized UGT1 mouse model expressing the UGT1A1 28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation. Drug Metab Dispos 38(5-879-886.
16. Toffoli G, et al. (2006) The role of UGT1A1 28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24(19-3061-3068.
17. Palomaki GE, Bradley LA, Douglas MP, Kolor K, Dotson WD (2009) Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 11(1-21-34.
18. Wallace BD, et al. (2010) Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330(6005-831-835.
19. Tobin P, et al. (2006) The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. Br J Clin Pharmacol 62(1-122-129.
20. Yamamoto M, et al. (2008) Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats. Oncol Rep 20(4-727-730.
21. Prijovich ZM, Chen KC, Roffler SR (2009) Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy. Mol Cancer Ther 8(4-940-946.
22. Takasuna K, et al. (2006) Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea. Cancer Chemother Pharmacol 58(4-494-503.
23. Strassburg CP, et al. (2000) Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 275(46- 36164-36171.
24. Strassburg CP, Nguyen N, Manns MP, Tukey RH (1999) UDP- glucuronosyltransferase activity in human liver and colon. Gastroenterology 116(1-149-160.
25. Strassburg CP, Manns MP, Tukey RH (1998) Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem 273(15-8719-8726.
26. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME (2000) Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60(5-1189-1192.
27. Khanna R, Morton CL, Danks MK, Potter PM (2000) Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res 60(17-4725-4728.
28. Nguyen N, et al. (2008) Disruption of the ugt1 locus in mice resembles human Crigler- Najjar type I disease. J Biol Chem 283(12-7901-7911.
29. Ruggiero A, Coccia P, Scalzone M, Attinà G, Riccardi R (2009) Treatment of childhood sarcoma with irinotecan: Bilirubin level as a predictor of gastrointestinal toxicity. J Chemother 21(6-693-697.
30. Iyer L, et al. (1999) Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65(5-576-582.
31. Iyer L, et al. (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101(4-847-854.
32. Grivennikov S, et al. (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15(2-103-113.
33. Grivennikov SI, et al. (2012) Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491(7423-254-258.
34. Hinoi T, et al. (2007) Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 67(20-9721-9730.
35. Wadkins RM, et al. (2004) Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: Synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol Pharmacol 65(6-1336-1343.
36. Hatfield MJ, et al. (2010) Biochemical and molecular analysis of carboxylesterasemediated hydrolysis of cocaine and heroin. Br J Pharmacol 160(8-1916-1928.
37. Strassburg CP, Manns MP, Tukey RH (1997) Differential down-regulation of the UDPglucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res 57(14-2979-2985.
38. Kacevska M, et al. (2011) Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism. Clin Cancer Res 17(10-3170-3180.
39. Xie W, et al. (2003) Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci USA 100(7-4150-4155.
40. Chen S, Yueh MF, Evans RM, Tukey RH (2012) Pregnane-x-receptor controls hepatic glucuronidation during pregnancy and neonatal development in humanized UGT1 mice. Hepatology 56(2-658-667.
41. Senekeo-Effenberger K, et al. (2007) Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation. Drug Metab Dispos 35(3-419-427.
42. Kühn R, Torres RM (2002) Cre/loxP recombination system and gene targeting. Methods Mol Biol 180:175-204.
43. Ghosh K, Van Duyne GD (2002) Cre-loxP biochemistry. Methods 28(3-374-383.
44. Le Y, Sauer B (2000) Conditional gene knockout using cre recombinase. Methods Mol Biol 136:477-485.
45. Utomo AR, Nikitin AY, Lee WH (1999) Temporal, spatial, and cell type-specific control of Cre-mediated DNA recombination in transgenic mice. Nat Biotechnol 17(11- 1091-1096.
46. Chen S, et al. (2005) Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. J Biol Chem 280(45-37547-37557.
47. Verreault M, et al. (2006) The liver X-receptor alpha controls hepatic expression of the human bile acid-glucuronidating UGT1A3 enzyme in human cells and transgenic mice. Hepatology 44(2-368-378.
48. Gagnon JF, Bernard O, Villeneuve L, Têtu B, Guillemette C (2006) Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin Cancer Res 12(6-1850-1858.